BioSpace News Archive

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), announced today the publication of “Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Identified a Novel Gene Signature in Responders to Ruxolitinib Cream,” in Transplantation and Cellular Therapy.

Peak Bio Co., Ltd., a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, and Ignyte Acquisition Corp., a special purpose acquisition company, announced they have entered into a definitive business combination agreement.

Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap.

MorphoSys AG will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes.

Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results for the first quarter 2022 before market open on Thursday, May 12, 2022.